{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:35:40Z","timestamp":1793932540723,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jns.2025.123617","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:34:56Z","timestamp":1752572096000},"page":"123617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia"],"prefix":"10.1016","volume":"476","author":[{"given":"Marta","family":"Campagnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Fiorenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Misenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cauzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Cagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Buss\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo Alessandro","family":"Fogliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mozzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Codemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gasparoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Moz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Narici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Corbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.123617_bb0005","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/mds.29419","article-title":"Defining the riddle in order to solve it: there is more than one Parkinson\u2019s disease","volume":"38","author":"Outeiro","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2025.123617_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106078","article-title":"Towards a biological diagnosis of PD","volume":"122","author":"Chopra","year":"2024","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2025.123617_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2025.123617_bb0020","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease","volume":"30","author":"Jack","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2025.123617_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.35328","article-title":"Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune-related adverse events during treatment with immune checkpoint inhibitors","author":"Schmitt","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jns.2025.123617_bb0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2025.123617_bb0035","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","article-title":"Plasma NfL, GFAP, amyloid, and p-tau species as prognostic biomarkers in Parkinson\u2019s disease","volume":"271","author":"Pilotto","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2025.123617_bb0040","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jama.2024.6619","article-title":"Changes in Alzheimer disease blood biomarkers and associations with incident all-cause dementia","volume":"332","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2025.123617_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-024-00768-1","article-title":"Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson\u2019s disease","volume":"10","author":"Pedersen","year":"2024","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.jns.2025.123617_bb0050","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2025.123617_bb0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2025.123617_bb0060","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123617_bb0065","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The Movement Disorder Society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2025.123617_bb0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2025.123617_bb0075","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.123617_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123283","article-title":"Optimal MMSE and MoCA cutoffs for cognitive diagnoses in Parkinson\u2019s disease: a data-driven decision tree model","volume":"466","author":"Fiorenzato","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2025.123617_bb0085","author":"Customer Portal"},{"key":"10.1016\/j.jns.2025.123617_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119975","article-title":"Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson\u2019s disease","volume":"565","author":"Chen","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jns.2025.123617_bb0095","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123617_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.625874","article-title":"Fixel-based analysis of white matter degeneration in patients with progressive Supranuclear palsy or multiple system atrophy, as compared to Parkinson\u2019s disease","volume":"13","author":"Nguyen","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jns.2025.123617_bb0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2025.123617_bb0110","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","article-title":"Reactive astrocytes: production, function, and therapeutic potential","volume":"46","author":"Liddelow","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jns.2025.123617_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108624","article-title":"Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease\u2013A systematic review","volume":"107","author":"Heimfarth","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jns.2025.123617_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-328547","article-title":"Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion","author":"Oeckl","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2025.123617_bb0125","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","article-title":"Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease","volume":"29","author":"Bellaver","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2025.123617_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257372","article-title":"Biomarkers of neurodegeneration and glial activation validated in Alzheimer\u2019s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson\u2019s disease","volume":"16","author":"Bartl","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jns.2025.123617_bb0135","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209418","article-title":"Association of Plasma Amyloid, P-tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies","volume":"102","author":"Bolsewig","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.123617_bb0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.11.010","article-title":"Inhibitors of NF-\u03baB and P2X7\/NLRP3\/caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer\u2019s disease","volume":"326","author":"Thawkar","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2025.123617_bb0145","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","article-title":"Inflammasome signalling in brain function and neurodegenerative disease","volume":"19","author":"Heneka","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2025.123617_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107255","article-title":"The effect of amyloid and tau co-pathology on disease progression in Lewy body dementia: a systematic review","volume":"131","author":"Tan","year":"2025","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2025.123617_bb0155","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jns.2025.123617_bb0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40035-021-00275-w","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia","volume":"10","author":"Zhu","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.jns.2025.123617_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","article-title":"Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias","volume":"14","author":"Baiardi","year":"2022","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.jns.2025.123617_bb0170","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1093\/geront\/gny126","article-title":"Can MoCA and MMSE be interchangeable cognitive screening tools? A systematic review","volume":"59","author":"Siqueira","year":"2019","journal-title":"Gerontologist"},{"key":"10.1016\/j.jns.2025.123617_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2025.123617_bb0180","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.123617_bb0185","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2025.123617_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jns.2025.123617_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/alz.091458","article-title":"Comparing the diagnostic performance of plasma pTau181 and pTau217 for the identification of Alzheimer\u2019s disease co-pathology in Lewy body disease","volume":"20","author":"Smith","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2025.123617_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13195-022-01011-w","article-title":"Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease","volume":"14","author":"Kac","year":"2022","journal-title":"Alz. Res. Ther."},{"key":"10.1016\/j.jns.2025.123617_bb0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2024.08.007","article-title":"Plasma p-tau181 and amyloid markers in Alzheimer\u2019s disease: a comparison between Lumipulse and SIMOA","volume":"143","author":"Quaresima","year":"2024","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2025.123617_bb0210","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13195-024-01630-5","article-title":"Analytical and clinical performance of eight Simoa\u00ae and Lumipulse\u00ae assays for automated measurement of plasma p-tau181 and p-tau217","volume":"16","author":"Wojda\u0142a","year":"2024","journal-title":"Alz. Res. Ther."},{"key":"10.1016\/j.jns.2025.123617_bb0215","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/brain\/awad330","article-title":"Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes","volume":"147","author":"De Meyer","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.123617_bb0220","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy","volume":"93","author":"Chouliaras","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:54:39Z","timestamp":1756281279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"alternative-id":["S0022510X25002345"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123617","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123617"}}